Diversify Advisory Services LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Diversify Advisory Services LLC bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 336 shares of the biopharmaceutical company’s stock, valued at approximately $234,000.

A number of other institutional investors have also made changes to their positions in REGN. International Assets Investment Management LLC boosted its position in Regeneron Pharmaceuticals by 86,013.3% during the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after purchasing an additional 879,916 shares during the period. Worldquant Millennium Advisors LLC bought a new position in Regeneron Pharmaceuticals during the 3rd quarter worth $127,489,000. Icon Wealth Advisors LLC raised its stake in Regeneron Pharmaceuticals by 18,342.0% in the third quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock valued at $79,874,000 after purchasing an additional 75,569 shares in the last quarter. State Street Corp raised its position in shares of Regeneron Pharmaceuticals by 1.3% in the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after buying an additional 61,277 shares in the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec raised its position in Regeneron Pharmaceuticals by 40.2% during the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 194,625 shares of the biopharmaceutical company’s stock valued at $204,598,000 after purchasing an additional 55,828 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Up 2.1 %

Shares of REGN stock opened at $694.64 on Friday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $666.25 and a 52-week high of $1,211.20. The company has a 50-day simple moving average of $730.57 and a two-hundred day simple moving average of $942.10. The company has a market capitalization of $76.33 billion, a price-to-earnings ratio of 17.19, a PEG ratio of 1.62 and a beta of 0.10. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. Barclays dropped their target price on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Morgan Stanley cut their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Wells Fargo & Company lowered their target price on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research report on Friday, January 10th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Finally, Canaccord Genuity Group began coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,015.38.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.